AUS
NZ
UK
CA
USA
IND
Highlights
Lumos Diagnostics announces new US partnership
Cleo Diagnostics progresses toward FDA filing
PYC Therapeutics reports clinical trial milestones
On Lamington Day, a symbol of accidental brilliance in Australian culinary history, the biotech sector delivered its own slice of news layered with trial progress, commercial deals, and strategic funding updates. Companies in diagnostics and drug development shared notable quarterly activity, reflecting momentum in innovation and execution.
Lumos Diagnostics Secures Major US Distribution Deal
Lumos Diagnostics (ASX:LDX), known for its rapid point-of-care testing technology, released its annual results alongside an important commercial update. The company's yearly revenue showed growth, although the June quarter saw a moderation in figures due to the seasonal end of flu activity in the US.
The focal point of Lumos' update was the announcement of a long-term distribution deal with a US-based partner for its Febridx test, designed to help healthcare providers distinguish between bacterial and viral infections. This agreement is set to significantly expand the availability of the test in international markets.
In addition to the partnership, Lumos shared that it had arranged a loan facility through its key shareholders, which enhances financial flexibility as the business scales its footprint in diagnostics.
Cleo Diagnostics Eyes Regulatory Milestone
In the diagnostics space, Cleo Diagnostics (ASX:COV) has laid out its plans for seeking regulatory approval for its ovarian cancer assay in the United States. The company expects to file its submission with the US Food and Drug Administration after concluding an ongoing supportive trial, targeted for completion by the end of the year.
Cleo's financial update showed a small net cash inflow, supported by government grants and tax incentives, allowing the company to maintain a solid reserve. Its focus remains on achieving successful clinical outcomes and positioning the assay for market readiness, particularly in addressing early detection challenges in women’s health.
PYC Therapeutics Advances in Rare Disease Programs
PYC Therapeutics (ASX:PYC) offered several important updates across its therapeutic pipeline. The company has commenced dosing in its combined Phase 1a/2b trial aimed at treating polycystic kidney disease, a genetic disorder with limited current options.
Additionally, PYC reported alignment with regulatory authorities on a trial structure for its leading candidate targeting retinitis pigmentosa type 11, a rare inherited retinal disease that can lead to vision loss. With significant funding reserves in place, the company appears well-positioned to continue its pursuit of therapies in under-addressed areas of medical need.
